|

Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation

RECRUITINGSponsored by Regina Elena Cancer Institute
Actively Recruiting
SponsorRegina Elena Cancer Institute
Started2024-11-04
Est. completion2027-11-04
Eligibility
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06894628

Summary

The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"

Eligibility

Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
* patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)

Exclusion Criteria:

* all exclusion criteria adopted for the "esSBRT" study.

Conditions2

CancerProstatic Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.